Elderly Man Sleeping in Bed

(Photo by SHVETS production from Pexels)

In a Nutshell

  • Blood levels of p-tau181, a protein linked to Alzheimer’s disease, were lowest in adults reporting 7 to 8 hours of sleep, started rising at about 8.5 hours, and climbed most sharply beyond 10 hours.
  • Short sleep, defined as 6 hours or less, was not associated with any of the four brain proteins measured.
  • Kidney function accounted for nearly all of the sleep-related differences in two other proteins tied to nerve damage and brain inflammation, but it did not explain away the p-tau181 signal.
  • Sleep was self-reported and measured once, so the study cannot establish cause and effect or rule out that long reported sleep simply reflects poor sleep quality.

Most people have heard the warnings about not getting enough sleep. A large new study points at the opposite extreme, suggesting that regularly sleeping too long may be a signal that something has already started to change inside the brain.

Researchers analyzing data from more than 2,400 older adults found that longer sleep was associated with higher blood levels of p-tau181, a protein tied to Alzheimer’s disease. Levels sat at their lowest in people reporting roughly 7 to 8 hours a night, began climbing at about 8.5 hours, and rose most sharply past 10 hours. That curve held up after researchers accounted for age, sex, genetics, sleep apnea, depression, and kidney function.

None of it means long sleep causes Alzheimer’s. Because the study captured everyone at a single moment in time, it cannot say which came first. But it raises a possibility that the study’s authors take seriously: heavy sleep may be less a sign of good rest and more a flag that early brain changes are already underway.

Woman sleeping in bed
Sleeping for more than 8.5 hours regularly could be linked to the development of Alzheimer’s-related blood proteins. (Photo by Unsplash+ In collaboration with Getty Images)

Inside the Alzheimer’s Blood Test at the Center of the Study

Phosphorylated tau 181, or p-tau181, is a form of the tau protein that turns up in the bloodstream when amyloid, the other hallmark protein of Alzheimer’s, begins driving chemical changes to tau inside the brain. Researchers use it to track the disease across groups of people, not to diagnose any one person. Its appeal to researchers is practical: it can be measured from an ordinary blood draw, no brain scan or spinal tap required, and it can register long before memory problems surface.

Scientists drew on the Framingham Heart Study, a research project in Framingham, Massachusetts, that has followed the health of multiple generations of residents since 1948. They examined blood samples and sleep reports from 2,410 adults with an average age of 70. Just over half were women, and roughly 86 percent were White.

Participants answered a straightforward question during a clinic visit: how many hours of sleep does a typical night bring? Researchers analyzed those answers two ways. One approach sorted people into three buckets, short sleepers at 6 hours or less, average sleepers between 6 and 9 hours, and long sleepers at 9 hours or more. A second approach treated sleep as a sliding scale and allowed for curved patterns instead of forcing a straight line through the data. Four blood proteins tied to Alzheimer’s, nerve damage, and brain inflammation were compared against both.

Sleep Window Linked to the Lowest Alzheimer’s Protein Levels

Only the curved analysis found the pattern. Charted that way, p-tau181 traced a J shape: a shallow dip centered on 7 to 8 hours, a gentle rise starting near 8.5 hours, then a steep climb past the 10-hour mark. Sorting the same people into three blunt categories showed nothing once health factors were accounted for, a mismatch the authors treat as the point rather than a footnote. Averaging everyone above 9 hours together, they argue, blurs the difference between a 9-hour sleeper and a 12-hour sleeper, which may be why past studies using different cutoffs have contradicted one another.

Kidney health mattered too. Two other proteins, one marking damage to nerve fibers and one tied to brain inflammation, initially looked related to long sleep. Once kidney function entered the models, those associations vanished, since failing kidneys clear such proteins from the blood more slowly and can inflate readings for reasons unrelated to the brain. P-tau181 was the exception. It stayed put.

Short sleep, which absorbs most of the public health attention, was not associated with any of the four proteins. That silence does not make skimping on sleep safe for the brain, and the authors offer a reason it might be misleading: short sleepers are a mixed group. Someone who genuinely needs six hours may be biologically different from someone lying awake with insomnia, and a single questionnaire cannot tell them apart.

Why Long Sleep May Signal Early Alzheimer’s Changes

Tau does not appear everywhere in the brain at once. It tends to collect first in small regions of the brainstem that regulate sleep and wakefulness, well before it reaches the areas responsible for memory. Damage there could disrupt the machinery that keeps a person alert, nudging sleep longer years before anyone notices a cognitive symptom. Under that reading, long sleep would be a downstream effect of early disease, not a cause of it.

A second explanation is more mundane and possibly overlapping. Self-reported sleep captures time in bed, not time asleep. People with fragmented sleep often compensate by staying in bed longer, so someone reporting 10 hours may be getting less deep, restorative sleep than someone reporting 7 solid ones. Deep sleep is when the brain flushes out waste proteins most efficiently, which means more hours of broken sleep could deliver less cleanup than fewer hours of unbroken sleep. This study did not measure sleep quality, so it cannot settle which explanation carries more weight, or whether both do.

For p-tau181 specifically, the pattern did not shift by age group, by sex, or by whether someone carried APOE ε4, the best-known genetic risk factor for Alzheimer’s. Consistency across those groups gives the finding more footing.

Among the 2,410 participants, 576 reported short sleep, 1,475 average, and 359 long. Long sleepers skewed older and had higher rates of depression and dementia, which raises the obvious worry that existing illness drove the whole result. Researchers deliberately left dementia and stroke out of the main models to avoid over-correcting, then reran the analysis with those participants removed. Findings held.

Other limits are harder to work around. Sleep came from self-report, capturing what people believe about their nights rather than anything measured. A single snapshot in time cannot say whether elevated p-tau181 preceded the long sleep or followed it. Relatively few people reported sleeping 10 or more hours, which is exactly where the effect looked largest and where the numbers are thinnest. And a sample that is roughly 86 percent White limits how far the results travel.

What the study does deliver is a specific number worth watching. Blood tests for Alzheimer’s are moving quickly from research labs toward clinics, and this analysis argues that a question doctors rarely ask, how long a patient sleeps, may belong alongside them. Authors of the paper call their own results hypothesis generating and want longer studies that track people over years with sleep monitors rather than questionnaires. Even so, they put forward a specific proposal: reported sleep beyond 9 to 10 hours a night may warrant a closer look at sleep and thinking skills, pending confirmation from that future work.

Disclaimer: This article describes a cross-sectional study, meaning researchers measured sleep and blood proteins at a single point in time rather than following participants as their health changed. That design can reveal that two things occur together, but it cannot establish that one causes the other, and it cannot show which came first. The findings do not mean that sleeping long causes Alzheimer’s disease, that shortening sleep would lower p-tau181 levels, or that any individual who sleeps more than nine hours has Alzheimer’s-related brain changes. Sleep duration was self-reported, and blood levels of p-tau181 are a research marker, not a diagnosis. Anyone with concerns about sleep or memory should speak with a physician rather than draw conclusions from a single study.

Paper Notes

Limitations

Several constraints shape how far these results travel. Sleep duration was self-reported to the nearest hour, which the authors note does not capture sleep quality, fragmentation, architecture, or the difference between time in bed and time actually asleep. The cross-sectional design means researchers observed associations at one moment and cannot determine whether elevated protein levels preceded longer sleep or followed it, nor whether changing sleep would alter biomarker trajectories. That same design leaves unresolved whether depression and sleep apnea act as confounders or as steps along the causal path, since causal ordering cannot be established empirically. Amyloid PET imaging and cerebrospinal fluid measures were unavailable, so amyloid positivity could not be directly confirmed. P-tau217, a newer marker, was not measured, though the authors note p-tau181 remains validated for Alzheimer’s pathology and correlates strongly with p-tau217. Associations were most pronounced at very long sleep durations of 9 to 10 hours or more, exactly where sample sizes are smallest, so replication in cohorts with more participants at those extremes would strengthen the inference. Finally, the sample was roughly 86 percent White, which limits generalizability to more diverse populations.

Funding and Disclosures

The Framingham Heart Study was supported by grants from the National Heart, Lung, and Blood Institute (contract numbers N01-HC-25195, HHSN268201500001I, and 75N92019D00031), the National Institute on Aging (R01 AG054076, R01 AG049607, U01 AG052409, R01 AG059421, RF1 AG063507, RF1 AG066524, and U01 AG058589), and the National Institute of Neurological Disorders and Stroke (R01 NS017950 and UH2 NS100605). Additional support came from the National Institutes of Health (P30 AG066546), the National Institute on Aging (AG0623531), the Alzheimer’s Association, NCATS (UM1 TR004538), the Sleep Research Society Foundation, the Fonds de recherche du QuĂ©bec en SantĂ©, the Canadian Institutes of Health Research, the Alzheimer Society of Canada, the Alzheimer Society of B.C., and a National Health and Medical Research Council of Australia Investigator Grant (GTN2009264). On disclosures, first author Vanessa M. Young is a PIA executive committee member of the Alzheimer’s Association and a member of its Sex and Gender & Sleep PIA work group. Senior author Sudha Seshadri reports consulting for Eisai and Biogen. AndrĂ©e-Ann Baril reports speaking fees from Eisai, and Arash Salardini reports speaking fees from Lilly. Christopher Frei’s institution has received research grants from Amgen, AstraZeneca, and Lilly over the past three years for research in cancer and infectious diseases. The remaining authors reported nothing to disclose.

Publication Details

Paper title: Non-linear associations between sleep duration and plasma p-tau181 in the Framingham Heart Study

Authors: Vanessa M. Young, Crystal Wiedner, AndrĂ©e-Ann Baril, Matthew P. Pase, Agustin Ruiz, Arash Salardini, Christopher R. Frei, Tiffany Kautz, Rebecca Bernal, Stephanie Yiallourou, Lachlan Cribb, Alexa Beiser, Antonio L. Teixeira, Jayandra Jung Himali, and Sudha Seshadri. Lead affiliation: Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, The University of Texas Health Science Center at San Antonio.

Journal: Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, Volume 22, Issue 5, article e71499 (2026). Research Article. Received December 26, 2025; revised March 23, 2026; accepted April 17, 2026.

DOI: 10.1002/alz.71499

Access: Open access under a Creative Commons Attribution-NonCommercial license.

Citation: Young VM, Wiedner C, Baril A-A, et al. Non-linear associations between sleep duration and plasma p-tau181 in the Framingham Heart Study. Alzheimer’s Dement. 2026;22:e71499.

About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor

Leave a Comment